目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. End Use outlook
2.2.3. Regional outlook
2.3. Competitive Insights

Chapter 3. Point Of Care Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Introduction of CLIA waived tests
3.2.1.2. Rise in funding from government and private institutions
3.2.1.3. Growing geriatric population base
3.2.1.4. Growing prevalence of target diseases
3.2.1.5. Growing demand for home healthcare and the introduction of advance technology enabled products
3.2.2. Market restraint analysis
3.2.2.1. High procedure costs coupled with limited adoption of POC devices in certain emerging regions
3.2.2.2. Presence of ambiguous regulatory as well as reimbursement frame work for primary care setting
3.2.3. Market challenge analysis
3.2.3.1. POC device pose challenges in maintaining the quality standards
3.2.4. Market opportunity analysis
3.2.4.1. Networking & remote integration of POC diagnostics products
3.2.4.1.1. Smartphone orientation
3.2.4.1.2. Embedded vision based solutions
3.2.4.1.3. Digital technologies
3.3. Point Of Care Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. Pricing Analysis, By Product
3.4.1. Glucose Testing
3.4.2. Hb1Ac Testing
3.4.3. Coagulation Testing
3.4.4. Fertility/Pregnancy
3.4.5. Infectious Disease
3.4.6. HIV POC
3.4.7. Clostridium Difficile POC
3.4.8. HBV POC
3.4.9. Pneumonia or Streptococcus Associated Infections
3.4.10. Respiratory Syncytial Virus (RSV) POC
3.4.11. HPV POC
3.4.12. Influenza/Flu POC
3.4.13. HCV POC
3.4.14. MRSA POC
3.4.15. TB and Drug-resistant TB POC
3.4.16. HSV POC
3.4.17. COVID-19
3.4.18. Other Infectious Diseases
3.4.19. Cardiac Markers
3.4.20. Thyroid Stimulating Hormone
3.4.21. Hematology
3.4.22. Primary Care Systems
3.4.23. Decentralized Clinical Chemistry
3.4.24. Feces
3.4.25. Lipid Testing
3.4.26. Cancer Marker
3.4.27. Blood Gas/Electrolytes
3.4.28. Ambulatory Chemistry
3.4.29. Drug of Abuse (DOA) Testing
3.4.30. Autoimmune Diseases
3.4.31. Urinalysis/Nephrology

Chapter 4. Point Of Care Diagnostics Market: Product Estimates & Trend Analysi
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Point Of Care Diagnostics Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Glucose Testing
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.2. Hb1Ac Testing
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.3. Coagulation Testing
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.4. Fertility/Pregnancy Testing
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5. Infectious Disease
4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.2. HIV POC
4.4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.3. Clostridium Difficile POC
4.4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.4. HBV POC
4.4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.5. Pneumonia or Streptococcus Associated Infections
4.4.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.6. Respiratory Syncytial Virus (RSV) POC
4.4.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.7. HPV POC
4.4.5.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.8. Influenza/Flu POC
4.4.5.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.9. HCV POC
4.4.5.9.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.10. MRSA POC
4.4.5.10.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.11. TB and drug resistant TB POC
4.4.5.11.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.12. HSV POC
4.4.5.12.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.13. COVID-19
4.4.5.13.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5.14. Other infectious diseases
4.4.5.14.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.6. Cardiac Markers
4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.7. Thyroid Stimulating Hormone
4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.8. Hematology
4.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.9. Primary Care Systems
4.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.10. Decentralized Clinical Chemistry
4.4.10.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.11. Feces
4.4.11.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.12. Lipid Testing
4.4.12.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.13. Cancer Marker
4.4.13.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.14. Blood Gas/Electrolytes
4.4.14.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.15. Ambulatory Chemistry
4.4.15.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.16. Drug of Abuse (DOA) Testing
4.4.16.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.17. Autoimmune diseases
4.4.17.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.18. Urinalysis/Nephrology
4.4.18.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Point Of Care Diagnostics Market: End Use Estimates & Trend Analysi
5.1. End Use Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Point Of Care Diagnostics Market by End Use Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Clinics
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD billion)
5.4.1.2. Pharmacy & Retail Clinics
5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.1.3. Physician Office
5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.1.4. Urgent Care Clinics
5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.1.5. Non-practice Clinics
5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.2. Hospitals
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.3. Home
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.4. Assisted Living Healthcare Facilitates
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.5. Laboratory
5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Point Of Care Diagnostics Market: Regional Estimates & Trend Analyss
6.1. Regional Market Share Analysis, 2023 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.5. North America
6.5.1. U.S.
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.2. Canada
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
6.6. Europe
6.6.1. Germany
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.2. UK
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.3. France
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/ reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.4. Italy
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework/ reimbursement structure
6.6.4.3. Competitive scenario
6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.5. Spain
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework/ reimbursement structure
6.6.5.3. Competitive scenario
6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.6. Russia
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework/ reimbursement structure
6.6.6.3. Competitive scenario
6.6.6.4. Russia market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.7. Norway
6.6.7.1. Key country dynamics
6.6.7.2. Regulatory framework/ reimbursement structure
6.6.7.3. Competitive scenario
6.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.8. Sweden
6.6.8.1. Key country dynamics
6.6.8.2. Regulatory framework/ reimbursement structure
6.6.8.3. Competitive scenario
6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.9. Denmark
6.6.9.1. Key country dynamics
6.6.9.2. Regulatory framework/ reimbursement structure
6.6.9.3. Competitive scenario
6.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
6.7. Asia Pacific
6.7.1. Japan
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.2. China
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.3. India
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.4. South Korea
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.5. Australia
6.7.5.1. Key country dynamics
6.7.5.2. Regulatory framework/ reimbursement structure
6.7.5.3. Competitive scenario
6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.6. Thailand
6.7.6.1. Key country dynamics
6.7.6.2. Regulatory framework/ reimbursement structure
6.7.6.3. Competitive scenario
6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
6.8. Latin America
6.8.1. Brazil
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework/ reimbursement structure
6.8.1.3. Competitive scenario
6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
6.8.2. Mexico
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework/ reimbursement structure
6.8.2.3. Competitive scenario
6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
6.8.3. Argentina
6.8.3.1. Key country dynamics
6.8.3.2. Regulatory framework/ reimbursement structure
6.8.3.3. Competitive scenario
6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
6.9. MEA
6.9.1. South Africa
6.9.1.1. Key country dynamics
6.9.1.2. Regulatory framework/ reimbursement structure
6.9.1.3. Competitive scenario
6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
6.9.2. Saudi Arabia
6.9.2.1. Key country dynamics
6.9.2.2. Regulatory framework/ reimbursement structure
6.9.2.3. Competitive scenario
6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
6.9.3. UAE
6.9.3.1. Key country dynamics
6.9.3.2. Regulatory framework/ reimbursement structure
6.9.3.3. Competitive scenario
6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
6.9.4. Kuwait
6.9.4.1. Key country dynamics
6.9.4.2. Regulatory framework/ reimbursement structure
6.9.4.3. Competitive scenario
6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.1.1. Abbott
7.3.1.2. Alere Inc.
7.3.1.3. F. Hoffmann-La Roche Ltd.
7.3.1.4. Siemens Healthcare GmbH
7.3.1.5. Danaher Corporation
7.3.1.6. Werfen
7.3.1.7. BD
7.3.2. Key customers
7.3.3. Key company market share analysis, 2023
7.3.4. Company Profiles
7.3.4.1. F. Hoffmann-La Roche Ltd.
7.3.4.1.1. Company overview
7.3.4.1.2. Financial performance
7.3.4.1.3. Product benchmarking
7.3.4.1.4. Strategic initiatives
7.3.4.2. Qiagen
7.3.4.2.1. Company overview
7.3.4.2.2. Financial performance
7.3.4.2.3. Product benchmarking
7.3.4.2.4. Strategic initiatives
7.3.4.3. Danaher Corporation
7.3.4.3.1. Company overview
7.3.4.3.2. Financial performance
7.3.4.3.3. Product benchmarking
7.3.4.3.4. Strategic initiatives
7.3.4.4. Becton Dickinson (BD)
7.3.4.4.1. Company overview
7.3.4.4.2. Financial performance
7.3.4.4.3. Product benchmarking
7.3.4.4.4. Strategic initiatives
7.3.4.5. bioMérieux
7.3.4.5.1. Company overview
7.3.4.5.2. Financial performance
7.3.4.5.3. Product benchmarking
7.3.4.5.4. Strategic initiatives
7.3.4.6. Abbott
7.3.4.6.1. Company overview
7.3.4.6.2. Financial performance
7.3.4.6.3. Product benchmarking
7.3.4.6.4. Strategic initiatives
7.3.4.7. Siemens Healthcare GmbH
7.3.4.7.1. Company overview
7.3.4.7.2. Financial performance
7.3.4.7.3. Product benchmarking
7.3.4.7.4. Strategic initiatives
7.3.4.8. Werfen
7.3.4.8.1. Company overview
7.3.4.8.2. Financial performance
7.3.4.8.3. Product benchmarking
7.3.4.8.4. Strategic initiatives
7.3.4.9. Nova Biomedical
7.3.4.9.1. Company overview
7.3.4.9.2. Financial performance
7.3.4.9.3. Product benchmarking
7.3.4.9.4. Strategic initiatives
7.3.4.10. Trividia Health, Inc.
7.3.4.10.1. Company overview
7.3.4.10.2. Financial performance
7.3.4.10.3. Product benchmarking
7.3.4.10.4. Strategic initiatives
7.3.4.11. QuidelOrtho Corporation
7.3.4.11.1. Company overview
7.3.4.11.2. Financial performance
7.3.4.11.3. Product benchmarking
7.3.4.11.4. Strategic initiatives
7.3.4.12. Trinity Biotech
7.3.4.12.1. Company overview
7.3.4.12.2. Financial performance
7.3.4.12.3. Product benchmarking
7.3.4.12.4. Strategic initiatives
7.3.4.13. Sekisui Diagnostics
7.3.4.13.1. Company overview
7.3.4.13.2. Financial performance
7.3.4.13.3. Product benchmarking
7.3.4.13.4. Strategic initiatives
7.3.4.14. Orasure Technologies, Inc.
7.3.4.14.1. Company overview
7.3.4.14.2. Financial performance
7.3.4.14.3. Product benchmarking
7.3.4.14.4. Strategic initiatives
7.3.4.15. Spectral Medical, Inc.
7.3.4.15.1. Company overview
7.3.4.15.2. Financial performance
7.3.4.15.3. Product benchmarking
7.3.4.15.4. Strategic initiatives
7.3.4.16. EKF Diagnostics Holdings plc.
7.3.4.16.1. Company overview
7.3.4.16.2. Financial performance
7.3.4.16.3. Product benchmarking
7.3.4.16.4. Strategic initiatives
7.3.4.17. Anbio Biotechnology Co., Ltd.
7.3.4.17.1. Company overview
7.3.4.17.2. Financial performance
7.3.4.17.3. Product benchmarking
7.3.4.17.4. Strategic initiatives
7.3.4.18. AccuBioTech Co., Ltd
7.3.4.18.1. Company overview
7.3.4.18.2. Financial performance
7.3.4.18.3. Product benchmarking
7.3.4.18.4. Strategic initiatives
7.3.4.19. ALPHA LABORATORIES
7.3.4.19.1. Company overview
7.3.4.19.2. Financial performance
7.3.4.19.3. Product benchmarking
7.3.4.19.4. Strategic initiatives
7.3.5. Company Market Positioning Analysis, 2023
7.3.5.1. Glucose Monitoring
7.3.5.2. Cardiac Markers
7.3.5.3. Hematology
7.3.5.4. Coagulation
7.3.5.5. Fertility Testing
7.3.5.6. Infectious Diseases
7.3.5.7. Decentralized Clinical Chemistry
7.3.5.8. Oncology Markers
7.3.5.9. Blood Gas Testing
7.3.5.10. Ambulatory Testing
7.3.5.11. Drug of Abuse
7.3.5.12. Urinalysis
7.3.6. Key Parameters
7.3.6.1. Company Size
7.3.6.2. Geographic Presence
7.3.6.3. Production Portfolio
7.3.6.4. Collaborations
7.3.7. Market Differentiators
7.3.7.1. Application Trends
7.3.7.2. Technology Trends
7.3.7.3. Test Location Trends
7.3.7.4. End-use Trends
7.3.7.5. Regional Trends
7.3.8. Private Companies
7.3.8.1. New Entrants/Emerging Players
7.3.9. Regional Mapping: Public and Private Companies

Chapter 8. Conclusion

List of Tables
Table 1 List of abbreviation
Table 2 North America point of care diagnostics market, by region, 2018 - 2030 (USD Billion)
Table 3 North America point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 4 North America point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 5 U.S. point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 6 U.S. point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 7 Canada point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 8 Canada point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 9 Europe point of care diagnostics market, by region, 2018 - 2030 (USD Billion)
Table 10 Europe point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 11 Europe point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 12 Germany point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 13 Germany point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 14 UK point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 15 UK point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 16 France point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 17 France point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 18 Italy point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 19 Italy point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 20 Spain point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 21 Spain point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 22 Russia point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 23 Russia point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 24 Denmark point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 25 Denmark point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 26 Sweden point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 27 Sweden point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 28 Norway point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 29 Norway point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 30 Asia Pacific point of care diagnostics market, by region, 2018 - 2030 (USD Billion)
Table 31 Asia Pacific point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 32 Asia Pacific point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 33 China point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 34 China point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 35 Japan point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 36 Japan point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 37 India point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 38 India point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 39 South Korea point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 40 South Korea point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 41 Australia point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 42 Australia point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 43 Thailand point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 44 Thailand point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 45 Latin America point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 46 Latin America point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 47 Brazil point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 48 Brazil point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 49 Mexico point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 50 Mexico point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 51 Argentina point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 52 Argentina point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 53 MEA point of care diagnostics market, by region, 2018 - 2030 (USD Billion)
Table 54 MEA point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 55 MEA point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 56 South Africa point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 57 South Africa point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 58 Saudi Arabia point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 59 Saudi Arabia point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 60 UAE point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 61 UAE point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
Table 62 Kuwait point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
Table 63 Kuwait point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)

List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Point of care diagnostics market: market outlook
Fig. 14 Point of care diagnostics competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Point of care diagnostics market driver impact
Fig. 20 Point of care diagnostics market restraint impact
Fig. 21 Point of care diagnostics market strategic initiatives analysis
Fig. 22 Point of care diagnostics market: Product movement analysis
Fig. 23 Point of care diagnostics market: Product outlook and key takeaways
Fig. 24 Glucose testing market estimates and forecast, 2018 - 2030
Fig. 25 Hb1Ac testing market estimates and forecast, 2018 - 2030
Fig. 26 Coagulation testing market estimates and forecast, 2018 - 2030
Fig. 27 Fertility/pregnancy market estimates and forecast, 2018 - 2030
Fig. 28 Infectious disease market estimates and forecast, 2018 - 2030
Fig. 29 HIV POC market estimates and forecast, 2018 - 2030
Fig. 30 Pneumonia or streptococcus associated infections market estimates and forecasts, 2018 - 2030
Fig. 31 Respiratory syncytial virus (RSV) POC market estimates and forecasts, 2018 - 2030
Fig. 32 HPV POC market estimates and forecasts, 2018 - 2030
Fig. 33 Influenza/ flu POC market estimates and forecasts, 2018 - 2030
Fig. 34 HCV POC market estimates and forecasts, 2018 - 2030
Fig. 35 MRSA POC market estimates and forecasts, 2018 - 2030
Fig. 36 TB and drug resistant TB POC market estimates and forecasts, 2018 - 2030
Fig. 37 HSV POC market estimates and forecasts, 2018 - 2030
Fig. 38 COVID-19 market estimates and forecasts, 2018 - 2030
Fig. 39 Other infectious diseases estimates and forecasts, 2018 - 2030
Fig. 40 Cardiac markers market estimates and forecasts, 2018 - 2030
Fig. 41 Thyroid stimulating hormone market estimates and forecasts, 2018 - 2030
Fig. 42 Hematology market estimates and forecasts, 2018 - 2030
Fig. 43 Primary care systems estimates and forecasts, 2018 - 2030
Fig. 44 Decentralized clinical chemistry market estimates and forecasts, 2018 - 2030
Fig. 45 Feces market estimates and forecasts, 2018 - 2030
Fig. 46 Lipid testing market estimates and forecasts, 2018 - 2030
Fig. 47 Cancer marker estimates and forecasts, 2018 - 2030
Fig. 48 Blood gas/ electrolytes market estimates and forecasts, 2018 - 2030
Fig. 49 Ambulatory chemistry market estimates and forecasts, 2018 - 2030
Fig. 50 Drug of abuse (DoA) testing market estimates and forecasts, 2018 - 2030
Fig. 51 Autoimmune diseases market estimates and forecasts, 2018 - 2030
Fig. 52 Urinalysis/nephrology market estimates and forecasts, 2018 - 2030
Fig. 53 Point of care diagnostics market: end use movement analysis
Fig. 54 Point of care diagnostics market: end use outlook and key takeaways
Fig. 55 Clinics market estimates and forecasts, 2018 - 2030
Fig. 56 Pharmacy & retail clinics market estimates and forecasts, 2018 - 2030
Fig. 57 Physician office market estimates and forecasts, 2018 - 2030
Fig. 58 Urgent care clinics market estimates and forecasts, 2018 - 2030
Fig. 59 Non-practice clinics market estimates and forecasts, 2018 - 2030
Fig. 60 Hospitals market estimates and forecasts, 2018 - 2030
Fig. 61 Home market estimates and forecasts, 2018 - 2030
Fig. 62 Assisted living healthcare facilities market estimates and forecasts, 2018 - 2030
Fig. 63 Laboratory market estimates and forecasts, 2018 - 2030
Fig. 64 Global point of care diagnostics market: Regional movement analysis
Fig. 65 Global point of care diagnostics market: Regional outlook and key takeaways
Fig. 66 Global point of care diagnostics market share and leading players
Fig. 67 North America market share and leading players
Fig. 68 Europe market share and leading players
Fig. 69 Asia Pacific market share and leading players
Fig. 70 Latin America market share and leading players
Fig. 71 Middle East & Africa market share and leading players
Fig. 72 North America: SWOT
Fig. 73 Europe SWOT
Fig. 74 Asia Pacific SWOT
Fig. 75 Latin America SWOT
Fig. 76 MEA SWOT
Fig. 77 North America, by country
Fig. 78 North America
Fig. 79 North America market estimates and forecasts, 2018 - 2030
Fig. 80 U.S. key country dynamics
Fig. 81 U.S. market estimates and forecasts, 2018 - 2030
Fig. 82 Canada country dynamics
Fig. 83 Canada market estimates and forecasts, 2018 - 2030
Fig. 84 Europe
Fig. 85 Europe market estimates and forecasts, 2018 - 2030
Fig. 86 UK country dynamics
Fig. 87 UK market estimates and forecasts, 2018 - 2030
Fig. 88 Germany country dynamics
Fig. 89 Germany market estimates and forecasts, 2018 - 2030
Fig. 90 France country dynamics
Fig. 91 France market estimates and forecasts, 2018 - 2030
Fig. 92 Italy country dynamics
Fig. 93 Italy market estimates and forecasts, 2018 - 2030
Fig. 94 Spain country dynamics
Fig. 95 Spain market estimates and forecasts, 2018 - 2030
Fig. 96 Russia country dynamics
Fig. 97 Russia market estimates and forecasts, 2018 - 2030
Fig. 98 Denmark country dynamics
Fig. 99 Denmark market estimates and forecasts, 2018 - 2030
Fig. 100 Sweden country dynamics
Fig. 101 Sweden market estimates and forecasts, 2018 - 2030
Fig. 102 Norway country dynamics
Fig. 103 Norway market estimates and forecasts, 2018 - 2030
Fig. 104 Asia Pacific
Fig. 105 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 106 China country dynamics
Fig. 107 China market estimates and forecasts, 2018 - 2030
Fig. 108 Japan country dynamics
Fig. 109 Japan market estimates and forecasts, 2018 - 2030
Fig. 110 India country dynamics
Fig. 111 India market estimates and forecasts, 2018 - 2030
Fig. 112 Thailand country dynamics
Fig. 113 Thailand market estimates and forecasts, 2018 - 2030
Fig. 114 South Korea country dynamics
Fig. 115 South Korea market estimates and forecasts, 2018 - 2030
Fig. 116 Australia country dynamics
Fig. 117 Australia market estimates and forecasts, 2018 - 2030
Fig. 118 Latin America
Fig. 119 Latin America market estimates and forecasts, 2018 - 2030
Fig. 120 Brazil country dynamics
Fig. 121 Brazil market estimates and forecasts, 2018 - 2030
Fig. 122 Mexico country dynamics
Fig. 123 Mexico market estimates and forecasts, 2018 - 2030
Fig. 124 Argentina country dynamics
Fig. 125 Argentina market estimates and forecasts, 2018 - 2030
Fig. 126 Middle East and Africa
Fig. 127 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 128 South Africa country dynamics
Fig. 129 South Africa market estimates and forecasts, 2018 - 2030
Fig. 130 Saudi Arabia country dynamics
Fig. 131 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 132 UAE country dynamics
Fig. 133 UAE market estimates and forecasts, 2018 - 2030
Fig. 134 Kuwait country dynamics
Fig. 135 Kuwait market estimates and forecasts, 2018 - 2030
Fig. 136 Market share of key market players- Point of care diagnostics market